Scholarlink

Introduction <p>Body mass index is an imperfect measure of excess adiposity but is ingrained in both research and clinical practice to define and diagnose adult obesity. The addition of waist circumference measure is recommended to fully capture obesity-related health risks at a population level. The latest reframing of obesity by the <i>Lancet Commission</i> relies on body mass index and waist circumference, as well as organ dysfunction and functional limitations, to differentiate between preclinical and clinical obesity.</p> Methods <p>Using data from the National Health and Nutrition Examination Survey (2005–2018), we adhere to the proposed redefinition to examine obesity trends in the adult U.S. population.</p> Results <p>In line with previously published estimates of obesity defined solely by body mass index, we show that the prevalence of both preclinical and clinical obesity increased between 2005 and 2018. However, the prevalence of preclinical obesity calculated by BMI plus WC is lower than the estimates derived from using BMI or WC as the sole metrics.</p> Conclusion <p>Using the <i>Commission’s</i> added measures yields refined population estimates for two categories—preclinical and clinical obesity. These updated estimates separate preclinical cases—at elevated risk and eligible for prevention—from those meeting clinical-obesity criteria, who require intervention.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Updated prevalence estimates of obesity among adults in the United States, 2005–2018

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月1日

查看全文
  • Ashley W. Kranjac,
  • Dinko Kranjac

摘要

Introduction

Body mass index is an imperfect measure of excess adiposity but is ingrained in both research and clinical practice to define and diagnose adult obesity. The addition of waist circumference measure is recommended to fully capture obesity-related health risks at a population level. The latest reframing of obesity by the Lancet Commission relies on body mass index and waist circumference, as well as organ dysfunction and functional limitations, to differentiate between preclinical and clinical obesity.

Methods

Using data from the National Health and Nutrition Examination Survey (2005–2018), we adhere to the proposed redefinition to examine obesity trends in the adult U.S. population.

Results

In line with previously published estimates of obesity defined solely by body mass index, we show that the prevalence of both preclinical and clinical obesity increased between 2005 and 2018. However, the prevalence of preclinical obesity calculated by BMI plus WC is lower than the estimates derived from using BMI or WC as the sole metrics.

Conclusion

Using the Commission’s added measures yields refined population estimates for two categories—preclinical and clinical obesity. These updated estimates separate preclinical cases—at elevated risk and eligible for prevention—from those meeting clinical-obesity criteria, who require intervention.